Aliso Viejo-based cancer and genetics testing providre Ambry Genetics said this morning that it is suing Myriad Genetics, in a response to a patent infringement lawsuit filed by Myriad and others against the company last month. Ambry Genetics claimed Myriad's patent lawsuit against the company is a violation of the Sherman Antitrust Act, and that Myriad is looking to monopolize testing of human BRCA1 and BRCA2 genes. Ambry said that Myriad's "anticompetitive conduct" means consumers have to pay "significantly higher prices" for cancer testing.
Top NewsTuesday, August 6, 2013
Ambry Genetics Countersues Myriad Genetics